MarginsXMarginsX
Home › Markets › Health Care › NEUP

Neuphoria Therapeutics Inc. (NEUP)

NEUP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.48
-2.75% on the day
Market cap
$13.4M
Nano cap
Revenue · 2026
$1.2M
-92.5% on 2025
Net income · 2026
-$13.5M
-1145.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1191070/000119312526395536/0001193125-26-395536-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-06-30.

Profile

FieldValue
TickerNEUP on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001191070
SEC industry codePharmaceutical Preparations
Incorporated inAustralia

Financials · 2026

LineValue
Revenue$1.2M
Net income-$13.5M
Operating income-$16.5M
Net margin-1145.7%
Operating margin-1401.1%
Revenue growth-92.5%
Cash$19.9M
Total assets$28.7M
P/E (computed)Net income was not positive
P/S (computed)11.4×

Warning signs

Cash runway
19.3 months
$19.9M cash at June 30, 2026
Share count, 1 year
+129.5%
2025-09-29 to 2026-09-17 · -95.6% over 3 years
Going-concern doubt
No
10-K filed September 18, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Consequently, management has determined there is no substantial doubt regarding the Company's ability to continue as a going concern for the twelve month period from the date these financial statements are issued."
10-K 2026-09-18
Cash and burn$19.9M cash; operating cash flow -$3.1M a quarter.Report 2026-06-30
Shares outstanding5,411,334 (2026-09-17); 2,357,613 a year earlier; 1,486,735,424 three years earlier. 3y figure adjusted for split (1-for-12 overall).Cover page 2026-09-17
Reverse splits, 3 years1; latest 1-for-12 on 2024-12-24Source 2024-12-24
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorWolf & Company, P.C., Boston, Massachusetts, United StatesPCAOB Form AP 2026-09-29
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q4 2026
2026-06-30
Not filed-$4.9M$1.2M$19.9MNo debt tags$1.2M10-K 2026-09-18
Q3 2026
2026-03-31
Not filed-$505K-$3.3M$19.4MNo debt tagsNeeds four quarters10-Q 2026-05-15
Q2 2026
2025-12-31
Not filed$1.9M-$6.4M$22.2MNo debt tagsNeeds four quarters10-Q 2026-05-15
Q1 2026
2025-09-30
Not filed-$9.9M-$3.8M$13.6MNo debt tagsNeeds four quarters10-Q 2026-05-15
Q4 2025
2025-06-30
-$13K-$8.9M-$3.6M$14.2MNo debt tags$15.6M10-K 2025-09-29
Q3 2025
2025-03-31
$15.0M$11.3M$11.5M$17.0MNo debt tagsNeeds four quarters10-Q 2026-05-15
Q2 2025
2024-12-31
$663K-$1.9M-$3.4M$4.3MNo debt tagsNeeds four quarters10-Q 2026-02-17
Q1 2025
2024-09-30
Not filed-$805K-$4.4M$8.1MNo debt tagsNeeds four quarters10-Q 2026-05-15

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS SUPPLEMENT
424B52025-11-14
Latest annual report10-K2026-09-18
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-11-16
Latest current report
CURRENT REPORT
8-K2026-10-23
Latest proxyDEFA14A2026-09-18

Source: SEC EDGAR submissions feed, 421 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-8.3%
1 month-24.8%
3 months-33.4%
Year to date-34.3%
1 year-46.3%
From 52-week high-53.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CMMBChemomab Therapeutics Ltd. American Depositary Share$1.62+5.88%$13.0M
MRKRMarker Therapeutics Inc.$0.8286-4.76%$13.8M
KYNBKyntra Bio Inc.$3.20-8.31%$13.0M
ALLRAllarity Therapeutics Inc.$0.8752-8.24%$13.9M
MCRBSeres Therapeutics Inc.$1.41+0.71%$14.4M
CTXRCitius Pharmaceuticals Inc.$0.5276-1.40%$14.5M
OPTHOptimi Health Corp. Common Shares$2.15-4.44%$12.3M
TVRDTvardi Therapeutics Inc.$1.10-6.78%$14.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier